inTrigue Business Case
Volv has spent three years developing its flagship product called inTrigue, which finds misdiagnosed and undiagnosed rare disease patients from electronic health care records (EHRs). inTrigue is based on an entirely original use of artificial intelligence and machine learning, together with a set of established in-country processes that access tens of millions of EHRs.
In a recent project, inTrigue was deployed for a biotech that had just received market authorisation for a rare metabolic disorder in eight countries, with a combined population of 428 million. Prior to the Volv project, the predicted number of affected (but undiagnosed) individuals in this population was believed to be 541, based on established prevalence figures. No incidence figures were known by the company, and it therefore had no estimate of growth of in treatable population. The inTrigue product determined a different prevalence, predicting 2,121 undiagnosed affected individuals, and it was also able to determine the incidence.